Bionest

Are the Blues Ending for Bluebird?

Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.

Bionest

Big Tech’s Foray in Healthcare

By bringing its unique strengths to specific health problems, can Big Tech play a larger role in many facets of healthcare?